ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RNA / options
MSLE (46) MENS (33) NBP (34) DERM (16) ⌘ Pro Terminal →

Atrium Therapeutics Inc. (RNA) Options Positioning, Max Pain & Unusual Sweeps

$8.55 +3.39% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.59

Atrium Therapeutics Inc. (RNA) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $141.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RNA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Atrium Therapeutics Inc. (NASDAQ: RNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $8.55 (+3.39% 1D, market cap $141.5M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, RNA ranks #396 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RNA compare to MSLE and MENS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MSLE (Satellos Bioscience Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $142.2M) and MENS (Jyong Biotech Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.8%, cap $142.9M). Among the 5-stock peer group, RNA leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RNA?
▼

Per RNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002093101), Atrium Therapeutics Inc. generated $3.5M in revenue, $0 in net income, and $0 in free cash flow against $8.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.59 (+0.42%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 112.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (10)Whales (5)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$18 Bull$8 Base$6 Bear
📬 FREE RNA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNA)Realized 20D OHLCV Swing Band: ±9.4%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY RNA SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 112.9% FCF Margin ($4.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$7.75+3% Next Q
Q2 (-2Q)
39
Grade E$7.98+4.3% Next Q
Q3 (-1Q)
41
Grade D$8.32+2.8% Next Q
Current
44
Grade D$8.55-6.5% Hist 90D α
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RNA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RNA currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.57) and Max Pain ($8.98) forces dealer call-delta covering toward $17.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RNA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±9.4%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (RNA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for RNA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNA)

  • ✓Walkthrough of RNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.57%📐 HORIZONTAL RANGE
2026-11-03O $8.26H $8.55L $8.26C $8.55VOL 566.7K
RES: $15.01SUP: $6.07SMA50: $9.57SMA200: $12.03
$15.18$13.10$11.01$8.93$6.84RES $15.01SUP $6.07$8.552026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNA Butterfly Map → + Track RNA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNA)

Health Care Rank #396 of 1015 ⚔️ MSLE vs RNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNA vs. MSLE, MENS, NBP, DERM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Atrium Therapeutics Inc. (RNA) ranks #396 by composite RQD confidence (44/100, grade D) and #612 by equity capitalization ($141.5M). Within this direct 5-issuer industry benchmark cohort, RNA leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. MSLE currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with RNA at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RNA ACTIVE
Atrium Therapeutics Inc.
D 44/100 — — — +3.39% $141.5M Benchmark Subject
MSLE
Satellos Bioscience Inc.
D 46/100 — — — -4.48% $142.2M /msle-vs-rna →
MENS
Jyong Biotech Ltd.
E 33/100 — — -28.8% -0.53% $142.9M /mens-vs-rna →
NBP
NovaBridge Biosciences
E 34/100 — — -35.0% -10.46% $137.9M /nbp-vs-rna →
DERM
Journey Medical Corporation
E 16/100 — 65.8% -19.5% -7.35% $145.9M /derm-vs-rna →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002093101 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atrium Therapeutics Inc. (RNA) reported GAAP revenue of $3.5M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, RNA closed FY2025 with $8.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.5M $0 — — $8.4M —

3. RNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Atrium Therapeutics Inc. (NASDAQ: RNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $8.55 (+3.39% 1D, market cap $141.5M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, RNA ranks #396 in composite RQD confidence.

How does RNA compare to MSLE and MENS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MSLE (Satellos Bioscience Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $142.2M) and MENS (Jyong Biotech Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.8%, cap $142.9M). Among the 5-stock peer group, RNA leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RNA?

Per RNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002093101), Atrium Therapeutics Inc. generated $3.5M in revenue, $0 in net income, and $0 in free cash flow against $8.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RNA trading relative to its 50-day, 200-day, and 52-week technical levels?

RNA last traded at $8.55 (+3.39% on volume of 470,085 shares), positioning the stock -10.66% below its 50-day simple moving average ($9.57) and -28.93% below its 200-day simple moving average ($12.03). Across its 52-week range of $7.49 to $16.77, RNA sits at the 11.4% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($7.75 to $9.35).

Direct Sub-Reports: RNA RQD Cockpit RNA 12M Forecast RNA Earnings & Move RNA Dividends & DRIP RNA Insiders & 13F RNA Whale Options RNA Profit Sankey RNA News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

RNA — Atrium Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Atrium Therapeutics Inc. (RNA) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $8.55 (+3.39% 1D, market capitalization $141.5M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Atrium Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Atrium Therapeutics Inc. (RNA) reported $3.5M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $8.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $7.49 – $16.77 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary signals are recorded. — for supply-chain bottleneck analysis. The private placement and the activist-style call for dilution transparency are the only ripple-relevant items in the source data; their second-order effects on share count and cash runway are not quantified in the sources.

  • Key Question #1: Can RNA sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.5M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RNA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RNA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Atrium Therapeutics Inc. (RNA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RNA Debate Forum (3) ↓
🟡 MARKET WIRE Benzinga • 1d ago
Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy

Data further reinforce scientific rationale for ATR 1072 targeting the root cause of PRKAG2 syndromeThe nonclinical results being presented at HCMS were generated in a new mouse model of PRKAG2 syndrome developed by

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RNA Bull vs. Bear Conversation Board — What's Your Call at $8.55?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RNA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RNA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $10.75 (+30.0%)
📌 Pinned Debate

The 15/20 Macro Regime Fit pillar, anchored by a beta of 1.0, indicates the stock's volatility profile is not an outlier relative to th

Here is why I am bullish on RNA here at $8.27: The 15/20 Macro Regime Fit pillar, anchored by a beta of 1.0, indicates the stock's volatility profile is not an outlier relative to the market.. Compare RNA's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $7.86 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — RNA's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $6.45 (-22.0%)
Spot @ $8.27

A 0% ROIC and 0% FCF yield, combined with an activist call to curb cash spending and explain dilutive financing, point to weak cash gen

I respect the product at Atrium Therapeutics Inc., but the stock at $8.27 is a different story. A 0% ROIC and 0% FCF yield, combined with an activist call to curb cash spending and explain dilutive financing, point to weak cash generation and dilution risk.. FCF yield is 0.0% and RQD sits at 44/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%